Promotion of Generic Drug Use and Intensifying Competition in the Pharmaceutical Market
First written in FY2016. 16 of 31 entries say "Materialised", first in FY2016. Latest entry: 2026-08-06.
Zeria Pharmaceutical moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 21 of 66 companies on the "Worse" side.
18 other companies' latest entry also says "Materialised".
- 2026-08-06MaterialisedEarnings
「当社子会社であるTillotts Pharma AGが保有する製品「ディフィクリア」の販売権につきましては、経済的便益の発生が期待される期間をもとに耐用年数を見積って償却しておりますが、今後の後発品参入可能性が高まったことから耐用年数を短縮し、将来にわたり変更しております。」
ディフィクリアへの後発品参入可能性の高まりが、販売権の耐用年数短縮と償却費増加として実際に反映された。 - FY2026WorsenedAnnual report
「When the patent period for one of our prescription drugs expires or the reexamination period prescribed by the relevant country ends, generic drugs are expected to enter the market. This may intensify competition in the prescription drug market and affect the performance and financial position of our Group.」
In addition to the existing risks associated with promoting generic drug use and market competition, the company explicitly identified the risk of generic entry following the expiration of patent and reexamination periods, making the threat to the product life cycle more specific. - FY2026-H1MaterialisedAnnual report
「The domestic market remained challenging due to drug price revisions, the selective reimbursement system for long-listed products and the impact of competing products, among other factors.」
Drug price revisions, the selective reimbursement system for long-listed products and the impact of competing products are clearly reflected in the challenging conditions in the domestic prescription drug market. - FY2025MaterialisedAnnual report
「Meanwhile, sales of the inflammatory bowel disease treatment Entocort declined due to the launch of generic drugs in some overseas countries.」
The risk of generic competition was actually reflected in lower overseas sales of Entocort during the fiscal year. - FY2024-Q1MaterialisedAnnual report
「Meanwhile, the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) struggled due to the impact of generic drugs being launched in some overseas countries.」
The launch of generic drugs was actually reflected in difficult overseas sales of Entocort / Zentacort. - FY2023WorsenedAnnual report
「In the pharmaceutical industry, the business environment for prescription drugs has become increasingly challenging as measures to contain healthcare costs, including annual drug price revisions and the promotion of generic drug use, have been pursued more forcefully than before. The OTC drug market also remained in a difficult environment, owing to intensifying market competition and sluggish inbound demand, among other factors.」
The business environment was described as increasingly challenging as annual drug price revisions, the promotion of generic drug use and intensifying competition in the OTC market continued, along with sluggish inbound demand. - FY2023-Q3MaterialisedAnnual report
「Although generic drugs were launched in some European countries last September, their impact remains limited.」
Generic drugs were in fact launched in some European countries, although the impact to date has been described as minor. - FY2023-Q2MaterialisedAnnual report
「Meanwhile, sales of the plant-based laxative Withone products declined due to the impact of competing products and other factors.」
The impact of competing products is clearly reflected in lower sales of Withone products. - FY2023-Q1MaterialisedAnnual report
「Meanwhile, sales of healthcare products, including the plant-based laxative Withone products and disinfectants, declined due to the impact of competing products and other factors.」
The impact of competing products is clearly reflected in lower sales of Withone products and healthcare products. - FY2022-Q3MaterialisedAnnual report
「Sales of the chondroitin product group, the With One plant-based laxative product group, and hygiene products, including disinfectants and antiseptics, declined due in part to the impact of competing products.」
The impact of competing products is clearly reflected in lower sales of the chondroitin products, Withone products and healthcare products. - FY2022-Q2RestatedAnnual report
「Sales of the With One plant-based laxative product group and hygiene products, including disinfectants and antiseptics, declined due in part to the impact of competing products.」
The impact of competing products continues to be reflected in lower sales of the With One product group and hygiene products. - FY2022-Q1Continued impact alongside a recovery trendAnnual report
「Although the company continues to be strongly affected by requests to refrain from going out and declining inbound demand, both the Hepalyse product group for drugstores, pharmacies, and dispensaries and the Hepalyse W product group for convenience stores are on a recovery trend.」
Although the effects of requests to refrain from going out and declining inbound demand associated with COVID-19 continue, the Hepalyse product group is described as being on a recovery trend. - FY2021-Q2MaterialisedAnnual report
「Sales of hygiene products, including disinfectants, increased. However, restrictions on going out associated with the spread of COVID-19, declining inbound demand and intensifying competition with other products caused the business as a whole to struggle, including its core products, the Hepalyse and Chondroitin ranges.」
As competition in the OTC market continued to intensify, the effects of COVID-19, including requests to refrain from going out and reduced inbound demand, added to the difficulties faced by the company’s main products. - FY2020WorsenedAnnual report
「Measures to contain medical costs, including a fundamental review of the drug pricing system and the promotion of generic drug use, were pursued more strongly than before, and domestic market growth is expected to slow inevitably going forward. Particularly for manufacturers of branded pharmaceuticals, the Ministry of Health, Labour and Welfare set a target of generic drugs accounting for at least 80% of volume by fiscal 2020. Generic drugs had already reached approximately 76.7% of volume as of the September 2019 drug price survey (Note 1), and the business environment is expected to become even more difficult.」
The generic drug volume share had risen to approximately 76.7%, approaching the policy target of at least 80%, indicating that the difficult environment surrounding branded drug manufacturers continued. The statement also describes intensifying competition in the OTC market and the impact of COVID-19. - FY2020-Q3RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals underwent a drug price revision in October 2019 accompanying the consumption tax increase, while the use of generic drugs continued to be strongly promoted as part of measures to contain medical costs. The OTC pharmaceutical market also continued to face intensifying competition.」
The drug price revision accompanying the consumption tax increase, promotion of generic drug use, and intensifying competition in the OTC market are described as continuing factors behind the difficult business environment. - FY2020-Q2RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. The use of generic drugs for prescription pharmaceuticals continued to be strongly promoted as part of measures to contain medical costs, while the OTC pharmaceutical market continued to face intensifying competition.」
The promotion of generic drug use and intensifying competition in the OTC pharmaceutical market are described as continuing factors behind the difficult business environment. - FY2020-Q1MaterialisedAnnual report
「Some products, including the With One product group, struggled amid intensifying market competition.」
It is stated that intensifying market competition was reflected in the performance of some products, including the With One product group, which struggled. - FY2019WorsenedAnnual report
「Measures to contain medical costs, including a fundamental review of the drug pricing system and promotion of generic drug use, were pursued more strongly than before, and domestic market growth is expected to slow inevitably going forward. Particularly for manufacturers of branded pharmaceuticals, the Ministry of Health, Labour and Welfare set a target of generic drugs accounting for at least 80% of volume between fiscal 2018 and the end of fiscal 2020. Generic drugs had already reached a 72.6% share of volume as of the September 2018 drug price survey, and the business environment is expected to become even more difficult.」
The generic drug volume share had risen to 72.6%, indicating the policy target of at least 80% and an outlook for slower growth in the domestic market. - FY2019-Q3RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals were subject to unexpected drug price reductions resulting from fundamental reform of the drug pricing system in April of the previous year, while measures to contain medical costs, including the promotion of generic drug use, were strongly pursued. The OTC pharmaceutical market also continued to face intensifying competition.」
Drug price reductions, the promotion of generic drug use, and intensifying competition in the OTC market are described as continuing factors behind the difficult business environment. - FY2019-Q2RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals were subject to unexpected drug price reductions resulting from fundamental reform of the drug pricing system in April, while measures to contain medical costs, including the promotion of generic drug use, were strongly pursued. The OTC pharmaceutical market also continued to face intensifying competition.」
Drug price reductions, the promotion of generic drug use, and intensifying competition in the OTC market are described as continuing factors behind the difficult business environment. - FY2019-Q1WorsenedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals were subject to unexpected drug price reductions resulting from fundamental reform of the drug pricing system in April, while measures to contain medical costs, including the promotion of generic drug use, were strongly pursued. The OTC pharmaceutical market also continued to face intensifying competition.」
Unexpected drug price reductions resulting from fundamental reform of the drug pricing system occurred, while the promotion of generic drug use and intensifying competition in the OTC market continued. - FY2018WorsenedAnnual report
「Particularly for manufacturers of branded pharmaceuticals, the Ministry of Health, Labour and Welfare set a target of generic drugs accounting for at least 80% of volume between fiscal 2018 and the end of fiscal 2020. Generic drugs had already reached a 65.8% share of volume as of the September 2017 drug price survey, and the business environment is expected to become even more difficult.」
The statement cites the policy target of a generic drug volume share of at least 80% and the 65.8% share reached as of September 2017, indicating that the environment for branded drug manufacturers is expected to become even more difficult. - FY2018-Q3MaterialisedAnnual report
「The chondroitin product group struggled due to intensifying market competition.」
It is stated that intensifying market competition was reflected in the performance of the chondroitin product group, which struggled. - FY2018-Q2MaterialisedAnnual report
「The pharmaceutical industry remained in a difficult environment. The use of generic drugs for prescription pharmaceuticals continued to be strongly promoted as part of measures to contain medical costs, while the OTC pharmaceutical market continued to face intensifying competition.」
The promotion of generic drug use and intensifying competition in the OTC market continued, and the pharmaceutical industry remained in a difficult environment. - FY2017RestatedAnnual report
「Prescription pharmaceuticals remained in a difficult environment as reviews of the drug pricing system and the promotion of generic drug use were pursued more strongly than before as part of measures to contain medical costs. The OTC pharmaceutical market also continued to face intensifying competition.」
The review of the drug pricing system, promotion of generic drug use, and intensifying competition in the OTC market are described as continuing factors behind the difficult environment. - FY2017-Q3RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals underwent a drug price revision in April of the previous year, while the use of generic drugs continued to be strongly promoted as part of measures to contain medical costs. The OTC pharmaceutical market also continued to face intensifying competition.」
The drug price revision, continued promotion of generic drug use, and intensifying competition in the OTC pharmaceutical market are described as a difficult business environment. - FY2017-Q2RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals underwent a drug price revision in April, while the use of generic drugs continued to be strongly promoted as part of measures to contain medical costs. The OTC pharmaceutical market also continued to face intensifying competition.」
The continued promotion of generic drug use and intensifying competition in the OTC market are described as a difficult business environment. - FY2017-Q1MaterialisedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals underwent a drug price revision in April, while the use of generic drugs continued to be strongly promoted as part of measures to contain medical costs. The OTC pharmaceutical market also continued to face intensifying competition.」
The continued promotion of generic drug use and intensifying competition in the OTC market are described as creating a difficult environment for the pharmaceutical industry. - FY2016MaterialisedAnnual report
「Prescription pharmaceuticals remained in a difficult environment as the use of generic drugs was promoted more strongly than before as part of measures to contain medical costs. The OTC pharmaceutical market also continued to face intensifying competition.」
It is stated that products including Asinon and Promac struggled due to the impact of increased generic drug use.